PDB2: IMPROVEMENT OF HEMOGLOBIN A1C (HBA1C) TESTING AND ANALYSIS OF PARTICIPANTREPORTED RESULTS IN CAREPATTERNS® FOR DIABETES PROGRAM  by Slezak, J et al.
327Abstracts
DIABETES—Clinical Outcomes/Healthcare Policy
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RELATION BETWEEN MEDICATION
COMPLIANCE AND GLUCOSE CONTROL IN
PATIENTS WITH TYPE 2 DIABETES
Shi SG1, Knight T1, Livengood KB2, Lubowski T2,Walden S2,
Nichol MB1
1University of Southern California, Los Angeles, CA, USA;
2Pﬁzer, Inc, New York, NY, USA
OBJECTIVES: To determine whether diabetes patients
who are more compliant with their medication therapy
tend to have a better glucose control. METHODS: The
analysis is based on clinical and survey data of 301
patients from 6 clinical centers in different regions of 
the U.S. Medication compliance is quantiﬁed from the
Morisky score, and the A1c fraction of glycosylated
hemoglobin (HbA1c) from a recent lab test is used to
measure glucose control. The relation between the two is
established with a general linear model controlling for a
set of covariates. The covariates include diabetes severity
proxies (the number of anti-diabetic agents, insulin vs.
non-insulin regimen, diabetes complications), length of
time with diabetes, demographic factors (age, gender, eth-
nicity), body mass index score (BMI), education level,
payment source, and clinic site. RESULTS: About 70%
of the diabetes patients in the sample were considered
compliant (Morisky score of 3 or greater). Compliance
patients had an HbA1c score 10% better or lower than
non-compliant patients, adjusted for covariates (p =
0.0003). As a by-product of the analysis, each additional
anti-diabetes medication was seen to be associated with
3.6% increase in HbA1c score. CONCLUSIONS: Self-
reported compliance with anti-diabetic medications
appears to be related to HbA1c. Future research should
correlate self-reported compliance with pharmacy claims,
and should be expanded to a different sample.
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IMPROVEMENT OF HEMOGLOBIN A1C (HBA1C)
TESTING AND ANALYSIS OF PARTICIPANT-
REPORTED RESULTS IN CAREPATTERNS® FOR
DIABETES PROGRAM
Slezak J, Hu L, Berger J
Caremark, Northbrook, IL, USA
OBJECTIVES: HbAlc is considered a cornerstone of dia-
betic care, a recognized clinical measure within diabetes
disease management and an important tool to help
patients assess their own diabetes management. This
study examines the frequency of participant-reported
HbAlc testing and improvement of results after the
Carepatterns® intervention. METHODS: Study partici-
pants enrolled in the program and were enrolled contin-
uously for at least 1 calendar year beginning in 2000.
They were asked if they received the Alc test from their
physician during their initial and annual telephonic
assessment calls. The result of the test was collected if
available. If the participant did not receive the test or did
not know if they had, they were educated on its impor-
tance. Participants were encouraged to ask their doctor
about testing and to discuss their results. Data were com-
piled and a 95% conﬁdence interval and corresponding
p-value was computed from the formula for the differ-
ence between 2 independent proportions and paired 
t-tests. RESULTS: Of 4257 study participants, 69% ini-
tially reported receiving an HbAlc test, and 83% at
annual for a D 14%, (95% CI 12%-16%, p < 0.05). An
analysis of 373 participant reported test values was per-
formed using a matched paired-t test when the value of
the test was provided during initial and annual assess-
ment. At initial assessment, mean test result of 7.02% was
reported and during their annual call, 6.76%. The mean
change 0.26 (95% CI 0.16 to 0.37 p < .05) was sig-
niﬁcant. CONCLUSIONS: These ﬁndings show that
CarePatterns® for diabetes program enrollees are
improving their compliance with the HbA1c test as well
as lowering their participant-reported test values after
participating in the program.
PDB3
EFFICACY OF INSULIN GLARGINE IN PATIENTS
WITH TYPE 1 AND 2 DIABETES
Plauschinat CA, Cryar AK, Godley PJ, Nguyen AB,
Browne BA
Scott & White Memorial Hospital,Temple,TX, USA
OBJECTIVES: Insulin glargine is a biosynthetic insulin
analog with a prolonged duration of action. Our objec-
tive is to determine the efﬁcacy of insulin glargine regard-
ing glycemic control in patients with Type 1 and 2
diabetes. A secondary objective is to determine potential
cost savings, if any, that may result from the use of insulin
glargine as an alternative to oral hypoglycemic agents in
patients with Type 2 diabetes. METHODS: A total of 135
patients with a diagnosis of Type 1 or 2 diabetes initiated
on insulin glargine by institutional endocrinologists from
April 2001 to September 2001 were included in this
study. Medical and pharmacy claims databases were ret-
rospectively analyzed 1 year pre- to 1 year post-initiation
of insulin glargine. Hemoglobin A1c (HbA1c), frequency
of hypoglycemic adverse events, and utilization of oral
hypoglycemic agents were evaluated. RESULTS: Average
HbA1c signiﬁcantly decreased by 0.31% from 8.48%
pre-glargine to 8.16% post-glargine (P = 0.012). The
overall frequency of hypoglycemia and nonsevere hypo-
glycemia were both signiﬁcantly lower in the post-
glargine period (69% vs. 36%, P < 0.001 and 38% vs.
19%, P < 0.01, respectively). In patients with Type 2 dia-
betes, a trend toward decreased utilization of oral hypo-
glycemic agents in the post-glargine period was observed
in the sulfonylureas, thiazoladinediones, and biguanides
(58.5% vs. 39%, P < 0.01). The use of insulin glargine
as an alternative to oral hypoglycemic agents resulted in
